Addex Therapeutcs

This clinical-stage pharmaceutical company develops orally available small molecule drugs known as allosteric modulators for neurological disorders. Its pipeline includes treatments for post-stroke recovery, substance use disorder, and chronic cough, utilizing a proprietary technology platform focused on mGlu and GABAB receptors. The company also supports spin-out ventures targeting conditions such as schizophrenia.